Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | NPR1 | P16066 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482825 | 0.94 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4473503 | 0.94 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL14434536 | 0.93 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065253 | 0.89 | MAT2A (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065579 | 0.89 | MAT2A (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1065255 | 0.89 | MAT2A (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3216490 | 0.85 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4473486 | 0.84 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4470456 | 0.84 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3223046 | 0.84 | SCN9A (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | claimed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | claimed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293348-A1 | Novel compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK13 43/4885MAPK12 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.